AATD gene editing race hinges on patient identification

In September 2026, three in vivo gene editing programs reported progress against the same rare disease, aimed at the same mutation. On September 7, YolTech reported patient data for YOLT-202 , an adenine base editor. A day later, Beam Therapeutics’ presentation of BEAM-302 data.